Ascophyllum nodosum, fucus vesiculosus and chromium picolinate nutraceutical composition can help to treat type 2 diabetic patients

Research output: Contribution to journalArticle

Abstract

Aim: To evaluate the actions of a combination of polifenolic composition (extracted from Ascophyllum Nodosum and Fucus Vesiculosus, InSea2®) and chromium picolinate compared to placebo in addition to previously taken anti-diabetic therapy in patients with type 2 diabetes. Methods: 175 Caucasian patients with type 2 diabetes were randomized to take nutraceutical combination or placebo for 6 months. One hundred and sixty-four cases completed the study. At baseline and after 6 months, glyco-metabolic control and lipid profile were evaluated. Results: Glycated hemoglobin was significantly reduced by the nutraceutical combination, but not by placebo, both compared to baseline (p<0.05), and compared to placebo (p<0.05). A similar trend was recorded for fasting plasma glucose (FPG) [−23.5% (p<0.01) vs baseline, and −18.0% (p<0.01) vs placebo] and post-prandial glucose (PPG) [−17.1% (p<0.01) vs baseline, and −11.1% (p<0.05) vs placebo]. No variations of lipid profile were recorded compared to baseline, even if it seems to observe a reduction trend of triglycerides level in the nutraceutical group. Conclusion: In conclusion, a nutraceutical combination of polifenolic composition and chromium picolinate in addition to previously taken anti-diabetic therapy can be helpful in reducing glycated hemoglobin in patients with type 2 diabetes mellitus.

Original languageEnglish
Pages (from-to)1861-1865
Number of pages5
JournalDiabetes, Metabolic Syndrome and Obesity: Targets and Therapy
Volume12
DOIs
Publication statusPublished - Jan 1 2019

Keywords

  • Ascophyllum Nodosum
  • Chromium
  • Fucus Vesiculosus
  • Glycemic control

ASJC Scopus subject areas

  • Internal Medicine
  • Pharmacology

Fingerprint Dive into the research topics of 'Ascophyllum nodosum, fucus vesiculosus and chromium picolinate nutraceutical composition can help to treat type 2 diabetic patients'. Together they form a unique fingerprint.

  • Cite this